Generic Name and Formulations:
Cisplatin 1mg/mL; soln for IV infusion after dilution.
Company:
Various generic manufacturers
As a single agent, for treating transitional cell bladder cancer.
Give by IV infusion over 6–8 hours. 50–70mg/m2 IV per cycle once every 3–4 weeks; heavily pretreated patients: initially 50mg/m2 IV per cycle every 4 weeks. Usual max: 100mg/m2 per cycle. Subsequent cycles: give as tolerated, withhold dose if serum creatinine, BUN, platelets, WBCs, or auditory acuity out of normal limits; see literature.
Not recommended.
Platinum coordination complex.
Renal or hearing impairment. Myelosuppression. Pregnancy (Cat.D). Nursing mothers.
Have epinephrine, antihistamine available. Monitor baseline and pre-treatment renal function, electrolytes, auditory function; do periodic CBCs (weekly), liver function tests, neurologic exam. Hydrate patient before dosing. Avoid extravasation. Elderly.
Potentiates nephrotoxicity with other nephrotoxic drugs (eg, aminoglycosides). May antagonize anticonvulsants. May be antagonized by pyridoxine.
Nephrotoxicity, neurotoxicity (eg, peripheral neuropathies), ototoxicity, myelosuppression, hemolytic anemia, marked nausea and vomiting, vascular toxicity (eg, MI, TIA), electrolyte disturbances, hyperuricemia, SIADH, hepatotoxicity, anaphylactic-like reactions, others; see literature.
Avoid contact with aluminum (eg, needles). Formerly known under the brand name Platinol.
Contact supplier.
As a single agent, for secondary therapy of metastatic ovarian tumor. Adjunctive therapy for ovarian tumor.
Give by IV infusion over 6–8 hours. 100mg/m2 IV per cycle once every 4 weeks; or, (when given with cyclophosphamide): 75–100mg/m2 IV per cycle once every 4 weeks. Usual max: 100mg/m2 per cycle. Subsequent cycles: give as tolerated, withhold dose if serum creatinine, BUN, platelets, WBCs, or auditory acuity out of normal limits; see literature.
Not recommended.
Platinum coordination complex.
Renal or hearing impairment. Myelosuppression. Pregnancy (Cat.D). Nursing mothers.
Have epinephrine, antihistamine available. Monitor baseline and pre-treatment renal function, electrolytes, auditory function; do periodic CBCs (weekly), liver function tests, neurologic exam. Hydrate patient before dosing. Avoid extravasation. Elderly.
Potentiates nephrotoxicity with other nephrotoxic drugs (eg, aminoglycosides). May antagonize anticonvulsants. May be antagonized by pyridoxine.
Nephrotoxicity, neurotoxicity (eg, peripheral neuropathies), ototoxicity, myelosuppression, hemolytic anemia, marked nausea and vomiting, vascular toxicity (eg, MI, TIA), electrolyte disturbances, hyperuricemia, SIADH, hepatotoxicity, anaphylactic-like reactions, others; see literature.
Avoid contact with aluminum (eg, needles). Formerly known under the brand name Platinol.
Contact supplier.
Adjunctive therapy for metastatic testicular tumor.
Give by IV infusion over 6–8 hours. 20mg/m2 IV daily for 5 days per cycle. Usual max: 100mg/m2 per cycle. Subsequent cycles: give as tolerated, withhold dose if serum creatinine, BUN, platelets, WBCs, or auditory acuity out of normal limits; see literature.
Not recommended.
Platinum coordination complex.
Renal or hearing impairment. Myelosuppression. Pregnancy (Cat.D). Nursing mothers.
Have epinephrine, antihistamine available. Monitor baseline and pre-treatment renal function, electrolytes, auditory function; do periodic CBCs (weekly), liver function tests, neurologic exam. Hydrate patient before dosing. Avoid extravasation. Elderly.
Potentiates nephrotoxicity with other nephrotoxic drugs (eg, aminoglycosides). May antagonize anticonvulsants. May be antagonized by pyridoxine.
Nephrotoxicity, neurotoxicity (eg, peripheral neuropathies), ototoxicity, myelosuppression, hemolytic anemia, marked nausea and vomiting, vascular toxicity (eg, MI, TIA), electrolyte disturbances, hyperuricemia, SIADH, hepatotoxicity, anaphylactic-like reactions, others; see literature.
Avoid contact with aluminum (eg, needles). Formerly known under the brand name Platinol.
Contact supplier.